Castellan Group Bristol Myers Squibb CO Transaction History

Castellan Group

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$57.89 - $64.73 $17,367 - $19,419	-300 Reduced 7.5%	3,700 $214,000
Q2 2023 Aug 14, 2023	SELL	$63.71 - $70.74 $1.7 Million - $1.89 Million	-26,725 Reduced 86.98%	4,000 $255,000
Q1 2023 May 17, 2023	SELL	$65.71 - $74.53 $10,842 - $12,297	-165 Reduced 0.53%	30,725 $2.13 Million
Q4 2022 Feb 16, 2023	BUY	$68.48 - $81.09 $1,095 - $1,297	16 Added 0.05%	30,890 $2.22 Million
Q3 2022 Nov 15, 2022	BUY	$0.13 - $76.84 $11 - $6,531	85 Added 0.28%	30,874 $2.2 Million
Q2 2022 Aug 15, 2022	SELL	$72.62 - $79.98 $97,673 - $107,573	-1,345 Reduced 4.37%	29,444 $2.27 Million
Q2 2022 Aug 15, 2022	BUY	$72.62 - $79.98 $97,673 - $107,573	1,345 Added 4.57%	30,789 $2.25 Million
Q1 2022 May 23, 2022	BUY	$61.48 - $73.72 $208,355 - $249,837	3,389 Added 12.37%	30,789 $2.25 Million
Q4 2021 Feb 16, 2022	BUY	$53.63 - $62.52 $179,660 - $209,442	3,350 Added 13.93%	27,400 $1.71 Million
Q3 2021 Nov 15, 2021	SELL	$59.17 - $69.31 $186,385 - $218,326	-3,150 Reduced 11.58%	24,050 $1.42 Million
Q2 2021 Aug 16, 2021	BUY	$61.91 - $67.42 $148,584 - $161,808	2,400 Added 9.68%	27,200 $1.82 Million
Q1 2021 May 14, 2021	BUY	$59.34 - $66.74 $89,010 - $100,109	1,500 Added 6.44%	24,800 $1.57 Million
Q4 2020 Feb 16, 2021	BUY	$57.74 - $65.43 $1.35 Million - $1.52 Million	23,300 New	23,300 $1.45 Million

2,533

1.47B

31.6M

35M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $125B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Castellan Group, based on Form 13F filings with the SEC.

Stay updated on Castellan Group with notifications on news.